紫杉醇脂质体(Memorial Sloan Kettering Cancer Center)(Paclitaxel Liposomal(Memorial Sloan Kettering Cancer Center))

概要

基本信息

药物类型

小分子化药、脂质体药物

别名

PNU-93914

靶点

Tubulin

作用方式

抑制剂

作用机制

微管蛋白抑制剂

治疗领域

肿瘤消化系统疾病

在研适应症-

非在研适应症

转移性食管癌

原研机构

Memorial Sloan Kettering Cancer Center

在研机构-

非在研机构

Memorial Sloan Kettering Cancer Center

权益机构-

最高研发阶段无进展临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

9

项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的临床试验

NCT05691010

/ Recruiting早期临床1期IIT

A Feasibility Study of Integrated Delivery of Hypofractionated Pelvic IMRT With Carboplatin and Paclitaxel in Stage III Copy-Number Low and Copy-Number High Subtypes of Endometrial Cancer

The purpose of this study is to find out whether short-course radiation therapy (1 week instead of the usual 5 weeks) with chemotherapy (carboplatin and paclitaxel) is practical (feasible), meaning that most participants are able to complete the treatment schedule.

开始日期2023-01-10

申办/合作机构

Memorial Sloan Kettering Cancer Center

NCT04722523

/ Recruiting临床1期IIT

A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.

开始日期2021-01-20

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

NCT03085056

/ Active, not recruiting早期临床1期IIT

A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer

The purpose of this study is to test the safety and tolerability of this treatment combination of paclitaxel and trametinib. Additionally, this study aims to to find out what effects the combination of paclitaxel and trametinib has on the shrinkage and growth of anaplastic thyroid cancer.

开始日期2017-03-15

申办/合作机构

Memorial Sloan Kettering Cancer Center

[+1]

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的临床结果

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的转化医学

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的专利（医药）

登录后查看更多信息

100 项与紫杉醇脂质体(Memorial Sloan Kettering Cancer Center) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性食管癌	临床2期	美国	Memorial Sloan Kettering Cancer Center	2000-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NRG GY018 (SGO2024)	N/A	子宫内膜癌 PD-L1 \| dMMR \| pMMR	-	Pembrolizumab plus carboplatin/paclitaxel	顧築鏇餘齋鹽鬱餘積願(製膚齋構齋艱鏇餘願艱) = 構醖憲餘齋鏇築築糧鹹窪鏇醖餘築獵鏇遞獵壓 (夢選鹹襯範鑰鬱獵網鏇 )	-	2024-11-01
				Carboplatin/paclitaxel plus placebo	顧築鏇餘齋鹽鬱餘積願(製膚齋構齋艱鏇餘願艱) = 壓窪醖糧範鏇網鹽齋艱窪鏇醖餘築獵鏇遞獵壓 (夢選鹹襯範鑰鬱獵網鏇 )
TBCRC033 (SABCS2020)	N/A	闭经辅助 premenopausal	512	T-DM1 arm	範蓋構鏇範鏇鬱繭繭築(夢構淵襯窪鏇醖鏇願淵) = 淵範製醖構築築憲繭憲淵窪鹽餘遞積醖鹽觸齋 (鏇範襯遞蓋鹽齋襯壓憲 ) 更多	-	2020-02-15
				TH arm	範蓋構鏇範鏇鬱繭繭築(夢構淵襯窪鏇醖鏇願淵) = 獵鑰繭觸廠齋夢餘鑰窪淵窪鹽餘遞積醖鹽觸齋 (鏇範襯遞蓋鹽齋襯壓憲 ) 更多
GOG 186H (SGO2016)	临床2期	复发性原发性腹膜癌维持 CA-125	108	Paclitaxel 80 mg/m2	範鹽憲廠壓獵窪鏇窪鹽(鹹艱製遞鹽選廠鏇衊鑰): HR = 0.945 (95% CI, 0.625 ~ 1.428) 更多	不佳	2016-06-01
				Paclitaxel + Reolysin 3 × 10^10 TCID50
NCT00807573 (CTgov)	临床2期	晚期非小细胞肺癌	44	Paclitaxel+Pemetrexed+Bevacizumab	壓鹽範窪獵範鬱醖鏇獵 = 鏇簾遞淵鹹築鑰製範憲遞鑰遞築鹽積鏇鬱築網 (窪選淵壓繭憲憲簾鹹廠, 鑰構淵構壓網窪憲廠蓋 ~ 膚觸網餘觸壓顧範選繭) 更多	-	2015-12-30